Figure 1. Micrographs of spinal cord motoneurons showing SOD1-immunoreactive inclusions.
Image credit: Forsberg, et. al. 2010 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email alsresearchforum@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! ALS Association Investigator-Initiated Multi-Year Research Grants
Sponsor: The ALS Association
Description: These grants support innovative research of high scientific merit and relevance to ALS. The maximum award is $100,000 USD per year for 3 years. Funding for multi-year grants is committed for one year only, with non-competitive renewals conditioned upon results. These applications require strong preliminary data.
Deadline: Abstracts due by January 31, 2017.



NEW! ALS Association Investigator-Initiated Starter Research Grants
Sponsor: The ALS Association
Description: These grants support innovative research of high scientific merit and relevance to ALS. Funding is for new investigators entering the field of ALS or senior fellows about to set up independently or pilot studies by current ALS investigators. The maximum award is $50,000 USD for 1 year. These applications do not require strong preliminary data but must emphasize innovation, scientific merit, feasibility and relevance to ALS.
Deadline: Abstracts due by January 31, 2017.



NEW! The Milton Safenowitz Postdoctoral Fellowship
Sponsor: The ALS Association
Description: This fellowship supports innovative postdoctoral research of high scientific merit and relevance to ALS. The maximum award is $50,000 USD per year for 2 years. Eligibility is limited to those who have been a fellow for 18 months or less.
Deadline: Abstracts due by January 31, 2017.



NEW! Robertson Neuroscience Investigator Awards
Sponsor: New York Stem Cell Foundation
Description: The goal of this initiative is to foster truly bold, innovative early career scientists with the potential to transform the field of neuroscience. Applicants are encouraged in the fundamental areas of developmental, cellular, cognitive, and translational neuroscience, broadly interpreted. The award is $1.5M USD over 5 years. Applicants need not be working in areas related to stem cells.
Deadline: Application due by February 22, 2017.



NEW! Robertson Stem Cell Investigator Awards
Sponsor: New York Stem Cell Foundation
Description: The goal of this initiative is to foster bold and innovative early career scientists with the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. The award is $1.5M USD over 5 years. In addition to providing funding, NYSCF partners with investigators to advance and translate their research.
Deadline: Application due by February 22, 2017.



NEW! Hudson Translational Team Grant
Sponsor: ALS Canada
Description: Only independent researchers working at Canadian institutions are eligible to apply. The grant will support teams of at least three researchers from a minimum of two institutions pursuing research with translational intent to accelerate therapeutic development for ALS.
Deadline: Letter of Intent due by March 25, 2017.



NEW! Identify and Characterize Potential Environmental Risk Factors for ALS and Evaluate Their Impact on ALS Disease Incidence and Progression
Sponsor: Centers for Disease Control and Prevention
Description: The ATSDR is soliciting investigator-initiated research that will identify and characterize environmental toxicants in human biological samples that may be potential environmental risk factors for ALS. Applications are also sought that will evaluate the impact of environmental toxicants on the development and progression of ALS, including gene-environment interactions. The award is $350,000 to $500,000 USD.
Deadline: Application due by March 31, 2017.



Improvement of Animal Models for Stem Cell-Based Regenerative Medicine
Sponsor: National Institutes of Health (NIH)
Description: This funding opportunity announcement (FOA) encourages applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.  The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.
Deadline: Application due by January 25, 2017.



NINDS Program Project Grant
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This funding opportunity is issued to enable submission of program project grant applications that propose to conduct innovative, interactive, high impact research.  Applications should address significant scientific questions about the brain and nervous system aimed to reduce the burden of neurological disease, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.
Deadline: Application due by January 25, 2017.



MNDRIA PhD Scholarship Top-up Grant
Sponsor: The Motor Neurone Disease Research Institute of Australia (MNDRIA)
Description: This grant is an incentive for an outstanding student with a top-up for the PhD stipend provided by their University.  The 3-year PhD top-up grant will be offered for a student who has been awarded a University PhD scholarship for biomedical or public health research in MND. Applicants must be PhD students who have commenced their PhD in 2015 or students who have applied to a University for a PhD scholarship to commence in 2016.
Deadline: Application due by January 27, 2017.



NINDS Research Project Grant (R01)
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the mission and research interests of NINDS.  
Deadline: Application due by February 5, 2017.



NINDS CREATE Bio Development Track – Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This Funding Opportunity Announcement (FOA) is dedicated to the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.  An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to the CREATE Bio Development Track. The FOA supports Investigational New Drug (IND)-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the U.S. Food and Drug Administration (FDA), at a minimum.  The program supports early-phase clinical trials, although these are not required. Available funding schemes: UH2/UH3 Phase Innovation Awards Cooperative Agreement U44 Small Business Innovation Research (SBIR) Cooperative Agreement
Deadline: Application due by February 8, 2017.



NINDS CREATE Bio Discovery Track – Optimization in Preparation for Development of Biotechnology Products and Biologics
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This Funding Opportunity Announcement (FOA) is dedicated to the discovery of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.  It supports the optimization of therapeutic lead(s) showing convincing proof-of-concept.   At the end of the funding period, projects that successfully advance through support from this program will have identified a optimized candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE Bio Development track for further development to enable filing for an Investigational New Drug (IND). Available funding schemes: U01 Research Project – Cooperative Agreements U44 Small Business Innovation Research (SBIR) Cooperative Agreement
Deadline: Application due by February 8, 2017.



NINDS CREATE Devices – Translational and Clinical Studies on the Path to 510(k)
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and clinical studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) or IRB approval for a Non-Significant Risk (NSR) study and the following clinical study. It is expected the immediate next steps upon completion of the clinical study will be a 510(k)/510(k) De Novo submission or a larger clinical trial that will lead directly to a 510(k)/510(k) De Novo submission. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and a small clinical study. Available funding schemes: UH2/UH3 Phase Innovation Awards Cooperative Agreement. U44 Small Business Innovation Research (SBIR) Cooperative Agreement.
Deadline: Application due by February 8, 2017.



NINDS CREATE Devices – Translational and Clinical Studies to Inform Final Device Design
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and clinical studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) or IRB approval for a Non-Significant Risk (NSR) study and the following clinical study. It is expected that the clinical study will inform a final device design that would have to go through most, if not all, of the preclinical testing on the path to more advanced clinical trials and market approval. This program also supports development of a device to test scientific hypotheses that are not feasible or practical to conduct in animal models, but are critical to enable next-generation devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and a small clinical study. Available funding schemes: UH2/UH3 Phase Innovation Awards Cooperative Agreement. U44 Small Business Innovation Research (SBIR) Cooperative Agreement.
Deadline: Application due by February 8, 2017.



NINDS CREATE Devices – Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE)
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and Early Feasibility Studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE), with the option of also supporting the following Early Feasibility Study.   It is expected the immediate next steps upon completion of the Early Feasibility Study will be a full Feasibility Study and a Pivotal Trial in support of a PMA (Pre-Market Approval) or HDE (Humanitarian Device Exemption). Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and an Early Feasibility Study. Available funding schemes: UH2/UH3 Phase Innovation Awards Cooperative Agreement. U44 Small Business Innovation Research (SBIR) Cooperative Agreement.
Deadline: Application due by February 8, 2017.



Development of Animal Models and Related Biological Materials for Research
Sponsor: National Institutes of Health (NIH)
Description: This funding opportunity announcement (FOA) encourages highly innovative research to develop, characterize or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes. The proposed project must fall within the categorical interests of two or more NIH institutions/centers. Applications to develop models that relate strictly to a specific disease or category of research will not be accepted and should be proposed to the appropriate categorical Institute or Center of the NIH.
Deadline: Application due by February 16, 2017.



Engineering Next-Generation Human Nervous System Microphysiological Systems
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) with improved fidelity to complex human brain, spinal, peripheral nervous system and/or sensory end organ circuit physiology in vivo, which will ultimately facilitate analysis of higher order functional deficits relevant to complex nervous system disorders.
Deadline: Application due by February 16, 2017.



Innovation Grants to Nurture Initial Translational Efforts (IGNITE) – Development and Validation of Model Systems or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease.  The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics. Ideally, endpoints proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings.  This FOA is not intended to support the development of animal and ex vivo model systems for the interrogation of disease etiology or for the identification of new drug targets. It is also not intended to support human clinical validation of model systems or pharmacodynamic markers. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.
Deadline: Application due by February 16, 2017.



Innovation Grants to Nurture Initial Translational Efforts (IGNITE) – Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.
Deadline: Application due by February 16, 2017.



Innovation Grants to Nurture Initial Translational Efforts (IGNITE) – Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamics, pharmacokinetics, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.
Deadline: Application due by February 16, 2017.



NINDS Exploratory-Developmental Research Grant Program
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Deadline: Application due by February 16, 2017.



NINDS Small Research Grant Program (R03)
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
Deadline: Application due by February 16, 2017.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by March 1, 2017.



Target ALS Research Consortia
Sponsor: Target ALS Foundation
Description: This award is focused on bringing investigators (3-6 laboratories) together to work collaboratively on the discovery and validation of ALS therapeutic targets. The maximum award is $130,000 per year per lab. The total award is up to $650,000 per year.
Deadline: Application due by March 6, 2017.



Bioengineering Research Partnerships
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Description: This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.
Deadline: Application due by May 18, 2017.



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Healthcare Research Grants
Sponsor: Motor Neurone Disease Association (MNDA)
Description: MNDA invests in research that fills knowledge gaps in clinical management of MND, adding to the evidence base and driving improvements in quality of care for people affected by MND.  
Deadline: Now accepting applications.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail